The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea

Sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Study ID
NCT07343635
Status
Recruiting
Apply to this trial

Conditions

  • Erythematotelangiectatic Rosacea

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Doxycycline — DRUG
    Doxycycline 100 mg orally once daily
  • Hydroxychloroquine — DRUG
    Hydroxychloroquine 200 mg orally twice daily.
  • Tofacitinib — DRUG
    Tofacitinib 5mg orally twice daily.
  • Anti-inflammatory Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) — DEVICE
    Topical application of Hirudoid followed by yellow light therapy (wavelength 590 nm, duration 20 minutes per session, once weekly)

Study Details

The efficacy and safety of anti-inflammation treatment (Hirudoid introduction followed by yellow light therapy) combined with tofacitinib and doxycycline in Chinese adult patients with mild to moderate erythematous telangiectatic rosacea: A prospective parallel controlled single-blind cohort study

Key Dates

Start date
Feb 1, 2026
Status verified
Mar 2026
Primary completion
Jul 1, 2027
Completion
Jul 1, 2027

Study Design

Enrollment
186 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Control group
    Participants receive doxycycline combined with hydroxychloroquine.
  • Active Comparator: Tofacitinib group
    Participants receive doxycycline combined with tofacitinib.
  • Experimental: Anti-inflammation Treatment and Tofacitinib group
    Participants receive doxycycline and tofacitinib combined with anti-inflammatory treatment.

Primary Outcome Measure

Achievement of IGA treatment success at Week 12 [ Time Frame: 0 week、12 week ]

Central Contacts